BTN3A1 and neoplasm: They demonstrated a single dose of γδ CAR-T-cells resulted in potent tumor growth inhibition in a xenograft mouse model (Wallet et al., 2021); Bispecific γδT lymphocyte conjugator (bsTCE) optimizes Vγ9Vδ2 Tumor targeted activation of T cells not only preserves the ability of immune cells to recognize and kill tumors, but also promotes the immune response against tumors (Labrijn et al., 2019); Humanized anti BTN3A (also called CD277) monoclonal antibody can selectively activate Vγ9Vδ2 T cells, and further stimulate the immune system to kill tumor cells (Harly et al., 2012).